Recent Updates
Recently added Catalysts

PF-06842874

Phase 1

Healthy Participants | Small molecule | Other |Pfizer, Inc.|Last Updated: Dec 6, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment44
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04124653A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy ParticipantsPHASE1 COMPLETED 44Oct 17, 2019Jul 26, 2021Dec 6, 20212 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Baseline up to 35 days after last dose of study medication

Treatment-related AEs are any untoward medical occurrences attributed to study drug in a participant who received study drug.

Number of Participants With Clinical Laboratory Abnormalities
Baseline up to 10 days after last dose of study medication

The following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick \[urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin\], microscopy \[urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous \[urine mucus and leucocytes\]).

Number of Participants With Clinically Significant Change From Baseline in Vital Signs
0, 1, 2, 3, 5, 8, 12, 24, and 48 hours post-dose

The following parameters will be analyzed for examination of vital signs: systolic blood pressure, diastolic blood pressure, and pulse rate.

Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings
0, 1, 2, 3, 5, 8, 12, 24, and 48 hours post-dose

Measurements of heart rate, PR interval, QT interval, QTc intervals, and QRS complex

Abnormal rhythms as observed continuous cardiac monitoring
0 to 8 hours post-dose

Cardiac rhythms measured by continuous cardiac telemetry

Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings
Baseline up to 10 days after last dose of study medication

A complete physical examination includes, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A limited physical examination includes, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms.

Secondary Endpoints
Maximum Observed Plasma Concentration (Cmax) of PF-06842874
0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours post-dose
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-06842874
0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-06842874
0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
PF-06842874/PlaceboEXPERIMENTALSingle dose administration of PF-06842874 or placebo
Relative BioavailabilityEXPERIMENTALDetermination of relative bioavailability of modified-release formulation relative to immediate-release formulation
Interventions
NameTypeDescription
PF-06842874DRUGSingle dose administration of PF-06842874
PlaceboDRUGSingle dose administration of placebo
Relative BioavailabilityDRUGRelative bioavailability assessment of modified-release formulation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Female participants of non-childbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) of 17.5 to 30.5 kg/m2...

Countries:United States
Unlock Eligibility Criteria